我如何跟踪霍奇金淋巴瘤在第一次完全 (代谢) 缓解?
1Division of Hematology, Clinical Hospital Merkur, 10000 Zagreb, Croatia.
Medicina (Kaunas, Lithuania)
|February 24, 2024
概括
霍奇金淋巴瘤的治愈率很高,但治疗会导致显著的长期副作用. 幸存者需要专门的多学科护理来管理并发病症并改善生活质量.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 霍奇金淋巴瘤 (HL) 的治愈率很高,但与治疗相关的并发症对幸存者构成重大风险.
- 治疗干预措施虽然有效,但可能导致长期健康问题影响生活质量.
研究的目的:
- 审查和分析霍奇金淋巴瘤幸存者的并发症.
- 评估生存问题,包括生育能力,二次癌症和生活质量.
- 探索复发检测和管理的最佳策略.
主要方法:
- 关于霍奇金淋巴瘤治疗和生存率的综合文献综述.
- 对有关长期毒性和并发症的数据进行分析.
- 评估当前和新兴的治疗策略,包括检查点抑制剂.
主要成果:
- 幸存者面临心血管毒性,二次恶性瘤和生育能力受损的风险.
- 治疗模式正在向最小化毒性转变,同时保持高治愈率.
- 像检查点抑制剂这样的新疗法显示出希望,但需要长期的毒性评估.
结论:
- 霍奇金淋巴瘤幸存者需要个性化,多学科的后续护理.
- 早期发现和管理长期治疗副作用对于改善生存率至关重要.
- 需要持续的研究才能充分了解新疗法的长期影响.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.1K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...